# CAPELA (NCT07222215)

> PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT07222215
- Phase: PHASE2
- Status: RECRUITING
- Sponsor: Kristina A. Fanucci
- Conditions: Estrogen-receptor-positive Breast Cancer; Metastatic Breast Cancer; Breast Cancer; Hormone Receptor Positive Breast Cancer; Human Epidermal Growth Factor 2 Negative Carcinoma of Breast; HER2- Breast Cancer; ESR1 Gene Mutation; ER Wildtype; Breast Neoplasms
- Interventions: Capecitabine; Elacestrant
- Enrollment: 297
- Primary outcome: Progression Free Survival (PFS) in ESR1 mutant population
- Primary outcome: Progression Free Survival (PFS) in intention to treat (ITT) population

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 2
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=capela-nct07222215